Digene
This article was originally published in The Gray Sheet
Executive Summary
Planned secondary offering of 2.5 mil. shares is withdrawn by the company March 19. Adverse market conditions are cited. The Gaithersburg, Maryland-based manufacturer of DNA tests for human papillomavirus notes that despite the move, "the company has a strong balance sheet and the financial resources to continue the execution of its growth strategy." Cash on hand stood at approximately $6.6 mil. as of Dec. 31. Second-quarter (ended Dec. 31) revenues were up 48% to $7.8 mil. A net loss of $1.6 mil. for the quarter was roughly even with that of the comparable quarter last year. Digene expects to file a PMA supplement by year-end for a primary screening indication of its HybridCapture 2 HPV test (1"The Gray Sheet" Feb. 26, 2001, p. 15)
You may also be interested in...
NCI HPV Trial Data Re-Evaluated By Digene To Support PMA Supplement
Digene will reanalyze clinical data and specimens from a 23,702-patient trial in Portland, Oregon, prior to seeking a primary screening indication for its HybridCapture 2 HPV test. The Gaithersburg, Maryland firm expects to file a PMA supplement by year-end.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.